Bibliography
- Khot UN, Khot MB, Bajzer CT, Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290(7):898-904
- Shlipak MG, Sarnak MJ, Katz R, Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352(20):2049-60
- Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006;113(8):1071-8
- Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2007;27(1):168-74
- Castillo L, Rohatgi A, Ayers CR, Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample. J Interferon Cytokine Res 2010;30(5):339-47
- Mateo T, Naim Abu Nabah Y, Abu Taha M, Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006;176(9):5577-86
- Tabibiazar R, Wagner RA, Deng A, Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice. Physiol Genomics 2006;25(2):194-202
- Cross DS, McCarty CA, Hytopoulos E, Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr Med Res Opin 2012;28(11):1819-30
- Tholen DW, Linnet K, Kondratovich M, Protocols for determination of limits of detection and limits of quantitation; approved guideline EP17-A. Clinical Laboratory and Standards Institute; Wayne PA, USA; 2004. p. 1-42
- McEnroe RJ, Burritt MF, Powers DM, Interference testing in clinical chemistry; approved guideline EP7-A2. 2nd edition. Clinical Laboratory and Standards Institute; Wayne PA, USA: 2005. p. 1-120
- Wilson PW, D'Agostino RB, Levy D, Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-47